nam/aidsmap, Published: 26 January 2016 Two statisticians involved in the PROUD and iPrEx trials of pre-exposure prophylaxis (PrEP) warn that future trials to test new PrEP drugs and formulations may be extremely difficult to design. David Dunn of the UK Medical Research Council and David Glidden of the University of California, San Francisco say that statisticians will need to choose and analyse...
Ipergay PrEP study results published
NAM , 02 December 2015 The results from the Ipergay study of intermittent pre-exposure prophylaxis (PrEP) were published in the New England Journal of Medicine (NEJM) on 1 December, World AIDS Day. The journal-published results are little changed from those presented at the CROI conference last February by principal investigator Jean-Michel Molina, but the researchers make a number of additional...
PrEP Is Safe for People With Hepatitis B
AIDSMEDS, August 17, 2015
People with hepatitis B virus (HBV) can safely take Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP), as it does not lead to liver inflammation “flares” or other health problems when it is used or discontinued.
Read more here
Men at high risk for HIV may misjudge their vulnerability
Many gay, bisexual and queer men who are good candidates for a drug that prevents HIV don’t believe their risk of being infected with the virus is high enough to warrant the drug’s use.